Core Viewpoint - The company Valiant Pharmaceuticals-B (09887) has seen a significant stock increase of nearly 6%, currently trading at 62.2 HKD, with a transaction volume of 11.42 million HKD, following the announcement of its dual-specific antibody LBL-034 receiving Fast Track designation from the FDA for the treatment of relapsed/refractory multiple myeloma (RRMM) [1] Group 1 - Valiant Pharmaceuticals announced that its proprietary TCE technology platform LeadsBody has developed the dual-specific antibody LBL-034, which has received Fast Track designation from the FDA [1] - This designation is a significant milestone in the international development of LBL-034, following its orphan drug designation received in October 2024, indicating further recognition of its clinical value and development strategy by international regulatory authorities [1] - LBL-034 is a humanized dual-specific T-cell engager targeting GPRC5D and CD3 [1]
港股异动 | 维立志博-B(09887)再涨近6% TCE双抗LBL-034获FDA快速通道资格认定